SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending as investors bet on the companys pivot from crypto mining to AI-focused data center infrastructure. The community is actively discussing rumors of imminent lease contracts and positive technical momentum, with many highlighting the potential for a rerating as the company integrates into major market indices.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following the release of positive Week 52 Phase 3 trial results, which investors are positioning as a strong best-in-class indicator for their skin drug, sonelokimab. The community is actively debating the potential for an upcoming acquisition and monitoring institutional accumulation, while some retail traders express frustration over recent price volatility and the timeline for further clinical data readouts.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as the market reacts to its latest acquisition of Cyberhawk, a critical infrastructure intelligence firm, alongside anticipation surrounding its upcoming inclusion in the Russell 2000 index. While the community is actively debating the company's aggressive acquisition-based growth strategy and the potential impact of its unified autonomous defense architecture, investors are closely monitoring the stock's consolidation patterns while waiting for further contract-based catalysts.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive topline Phase 3 data for its depression treatment, triggering significant investor interest and ongoing debate regarding its potential for commercial success against established psychedelic peers. Community discussions center on the company's clinical trial catalysts, cash runway, and the binary nature of upcoming data readouts in the competitive mental health space.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community interest as high volume and unusual pre-market activity fuel speculation regarding a potential buyout or upcoming catalyst for the AUR200 pipeline. Investors are closely monitoring CEO Kevin Tang's significant share accumulation while debating the impact of ongoing patent litigation and the strategic silence from the new management team.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF (DRAM) is trending as investors capitalize on the structural AI-driven demand for HBM and storage, despite broader market volatility and uncertainty surrounding major upcoming IPOs. Community sentiment remains overwhelmingly bullish, with many participants framing the current price action as a strategic entry point for a long-term re-rating of the memory sector beyond its traditional cyclical history.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as investors aggressively bid up memory stocks, fueled by reports of structural storage shortages and AI-driven data center demand. The community is actively debating the sustainability of this parabolic run, with some traders highlighting the stock's record-setting RSI as a sign of an overheating market while others point to institutional re-rating as evidence of a sustained supercycle.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing significant volatility following a surprise FDA clinical hold on its gene therapy programs, which triggered investor anxiety ahead of a looming PDUFA date for its Hunter syndrome therapy. While the community remains deeply divided between those citing the potential for an approval and those betting on a complete response letter (CRL) due to safety concerns, investors are actively analyzing how this regulatory setback impacts the long-term viability of the company's broader AAV vector pipeline.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is under intense focus as China implements new export controls and security reviews on critical minerals, prompting community debate over domestic supply chain independence and the effectiveness of existing government partnerships. Investors are closely monitoring how the company handles compliance and competitive pressures while weighing the broader geopolitical implications of restricted dual-use material access for the U.S. defense industrial base.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant selling pressure and heightened volatility, as investors weigh concerns over subscriber growth against management's capital allocation and potential M&A activity. The community remains deeply polarized, with bears aggressively betting on further downside following recent technical breaks, while bulls are scouting for value in what they consider an oversold market leader.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Key Points814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share...

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new...

Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy

AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

Equity

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Inc. Profit Advances In Q1

(RTTNews) - Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for its first quarter that Increased, from last year...

Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +20.83% and +2.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 9,112,230 shares, a decrease of 15.7% from the March 31st total of 10,809,496 shares...

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are speculating on a potential acquisition after unusual volume and persistent chatter about the CEO's strategic positioning.

Traders are closely tracking high-volume premarket spikes that have pushed share prices toward multi-year highs.

Discussion is buzzing around recent executive stock accumulation, with shareholders viewing it as a strong signal of upcoming positive developments.

Bullish participants are rallying against short sellers, hoping for a sharp move upward as price action tests technical resistance levels.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.24	--	--	N/A
Q1 '26	$0.19	$0.25	28.21%	BEAT
Q4 '25	$0.22	$1.53	606.15%	BEAT
Q3 '25	$0.16	$0.23	43.75%	BEAT
Q2 '25	$0.15	$0.16	9.09%	BEAT

AUPHAurinia Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest AUPH News